M. Cadoz

发表

Tetravalent (A, C, Y, W 135) meningococcal vaccine in children: immunogenicity and safety.

M. Cadoz, J. Armand, F. Arminjon, 1985, Vaccine.

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.

D. Bernstein, S. Plotkin, M. Schleiss, 2002, The Journal of infectious diseases.

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report.

R. Thapa, R. Schneerson, J. Robbins, 1987, The New England journal of medicine.

PROTECTIVE ACTIVITY OF VI CAPSULAR POLYSACCHARIDE VACCINE AGAINST TYPHOID FEVER

R. Schneerson, H. Koornhof, K. Klugman, 1987, The Lancet.

Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine

A. Siitonen, P. Oksanen, H. Peltola, 1991, The Lancet.

The acellular pertussis vaccine trials: an interpretation.

S. Plotkin, M. Cadoz, 1997, The Pediatric infectious disease journal.

Potential and limitations of polysaccharide vaccines in infancy.

M. Cadoz, 1998, Vaccine.

The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age.

M. Levine, J. Clemens, L. Avila, 1991, The Pediatric infectious disease journal.

Acellular pertussis vaccines: evaluation of reversion in a nude mouse model.

M. Cadoz, J. Armand, F. Arminjon, 1988, Journal of biological standardization.

Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones.

B. Guy, T. Monath, J. Haensler, 2001, FEMS immunology and medical microbiology.

PNEUMOCOCCAL SEROTYPES IN WEST AFRICA

B. Greenwood, J. Chiron, M. Hassan-King, 1980, The Lancet.

[An epidemiological study of purulent meningitis cases admitted to hospital in Dakar, 1970-1979].

F. Denis, M. Cadoz, I. Mar, 1981, Bulletin of the World Health Organization.

New and Improved Techniques for Vaccine Production

B. Montagnon, M. Cadoz, J. Armand, 1989 .

A new 23 valent pneumococcal vaccine: immunogenicity and reactogenicity in adults.

J. Michel, M. Cadoz, J. Armand, 1985, Journal of biological standardization.

Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants

F. Simondon, S. Wassilak, M. Cadoz, 1996, European Journal of Clinical Microbiology and Infectious Diseases.

Vaccin anti-Haemophilus influenzae*

P. Reinert, L. Hessel, M. Cadoz, 1989 .

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.

W. Cox, É. Gönczöl, S. Plotkin, 2001, The Journal of infectious diseases.

Acellular vaccine efficacy trials.

S. Plotkin, M. Cadoz, 1997, The Pediatric infectious disease journal.

Applications pratiques de la vaccination méningococcique

M. Cadoz, P. Saliou, N. Cam, 1991 .

CMV Vaccines to Prevent Congenital Infection

M. Cadoz, C. Méric, 2003 .

The safety and use of canarypox vectored vaccines.

E. Paoletti, J. Tartaglia, J. Excler, 1995, Developments in biological standardization.

[Bacteriological, pharmacological and clinical comparison between amoxycillin and ceftriaxone in the treatment of 300 purulent meningitis ].

F. Denis, M. Cadoz, T. Guerma, 1982, Pathologie-biologie.

Immunisation with canarypox virus expressing rabies glycoprotein

E. Paoletti, J. Tartaglia, S. Plotkin, 1992, The Lancet.

Assessment of Helicobacter pylori Gene Expression within Mouse and Human Gastric Mucosae by Real-Time Reverse Transcriptase PCR

B. Guy, M. Cadoz, E. Vidor, 2001, Infection and Immunity.

Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones.

B. Guy, T. Monath, J. Haensler, 2001, FEMS immunology and medical microbiology.

EMERGENCE OF MENINGOCOCCAL MENINGITIS CAUSED BY W135 SEROGROUP IN AFRICA

J. Etienne, P. Saliou, F. Denis, 1982, The Lancet.

Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori.

B. Guy, T. Monath, Subhas Banerjee, 2002, Vaccine.

Treatment of purulent meningitis with a new cephalosporin-Rocephin (Ro 13-9904). Clinical, bacteriological and pharmacological observations in 24 cases.

F. Denis, M. Cadoz, I. Diop Mar, 1981, Chemotherapy.

Meningitis caused by Hemophilus influenzae type C.

J. Chiron, F. Denis, M. Cadoz, 1978, The Journal of pediatrics.

Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines.

M. Levine, C. Tacket, J. Robbins, 1986, The Journal of infectious diseases.

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

S. Mboup, F. Simondon, I. Iteman, 1997, Vaccine.

Challenge model for Helicobacter pylori infection in human volunteers

D. Graham, T. Monath, Y. Yamaoka, 2004, Gut.

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

W. Cox, S. Plotkin, S. Pincus, 1999, The Journal of infectious diseases.

Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa.

M. Georges-Courbot, L. Bélec, V. Gouvea, 1991, Research in virology.

[Spinal concentrations of amoxicillin in purulent meningitis in children].

F. Denis, M. Cadoz, O. Diouf, 1983, Pathologie et biologie.

[Tolerance and immunogenicity of the capsular polyoside vaccine against Haemophilus influenzae type b. A study of 325 children 15 to 71 months of age].

P. Reinert, L. Hessel, M. Cadoz, 1989, Annales de pediatrie.

Clinical and immunologic responses to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants injected at 3, 5, 7, and 18 months of age.

J. C. Parke, R. Schneerson, J. Robbins, 1991, The Journal of pediatrics.